Recently, a number of domestic new drugs have been approved for marketing at home and abroad

According to the recent announcements of major pharmaceutical companies, NMPA and other information, a large number of domestic new drugs have been approved for marketing since March, and more than ten drugs have been approved for marketing at home and abroad since March, involving Hansoh Pharmaceutical and Junshi Biotechnology.
, Sinopharm Group, Heyi Pharmaceutical and other enterprises
.
Sinopharm Group's Doxofylline Injection Marketing Application Accepted Recently, Sinopharm Group's marketing application for doxofylline injection, which is a generic type 4 application, has been accepted by CDE.
The drug is used to treat bronchitis and other diseases
.
According to data from Minet.
com, in 2020, the sales of terminal doxofylline injection in China's public medical institutions exceeded 1.
9 billion yuan
.
The data show that doxofylline is a derivative of methylxanthine.
It is a bronchodilator.
It relaxes bronchial smooth muscle by inhibiting phosphodiesterase in smooth muscle cells, thereby achieving the effect of inhibiting asthma.
It is mainly used for Treatment of bronchial asthma, asthmatic chronic bronchitis and other dyspnea caused by bronchospasm
.
Heyi Pharmaceutical's lidocaine hydrochloride ophthalmic gel was approved for marketing On March 24, the website of the State Food and Drug Administration showed that Sichuan Heyi Pharmaceutical's lidocaine hydrochloride ophthalmic gel was approved for marketing, which is the top domestic lidocaine Ophthalmic gel
.
Lidocaine hydrochloride amide local anesthetics have obvious bidirectional effects of excitation and inhibition on the central nervous system, mainly used for infiltration anesthesia, epidural anesthesia, surface anesthesia, nerve conduction block,
etc.
Data shows that in 2020, the sales of terminal lidocaine in China's public medical institutions exceeded 600 million yuan
.
In the first half of 2021, sales increased by 37.
17% year-on-year
.
On March 23, Hanyu Pharmaceutical announced that the company recently learned through the website of the Brazilian Health Supervision Agency (ANVISA) that the company's agent seller of terlipressin preparations for injection, VOL Pharma Obtained the approval of the Brazilian marketing authorization for this product
.
According to reports, terlipressin is a synthetic vasopressin analog, which belongs to the vasoconstrictor drug in vasoactive drugs, and is mainly used for hemostasis of variceal bleeding in liver cirrhosis.

.
It is now widely used in the treatment of hepatorenal syndrome, liver cirrhosis, ascites, septic shock, burns, acute liver failure, cardiac arrest,
etc.
On March 18, the NMPA officially approved the new indication of domestic ALK targeted drug, and Betta Pharmaceuticals' ALK inhibitor ensatinib capsule was approved for the new indication for the first-line treatment of ALK-positive NSCLC
.
This is a new indication for the drug that has been approved again recently
.
According to the data, Ensatinib is the first domestic ALK inhibitor approved for marketing.
On November 19, 2020, the China National Medical Products Administration (NMPA) released information, and Betta Pharmaceuticals submitted the ALK inhibitor Ensatinib hydrochloride.
The marketing application of Ni Capsules (trade name: Bemena) was approved
.
At present, it has entered the new version of the medical insurance catalog through medical insurance negotiation
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.